secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organogenesis Holdings Inc. (ORGO)
CIK:        0001661181
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093893
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organogenesis Q2 revenue up 11% but net loss $17M on $22.8M impairment and write-downs
--------------------------------------------------------------------------------

- Net revenue $130.2M (+11% YoY); Advanced Wound Care $123.2M (+12%), Surgical & Sports Med $7.0M (-3%).
- Net loss $17.0M ($0.13/sh) vs net income $5.3M Q2 2023; included $18.8M impairment and $4.0M software write-down.
- Adjusted EBITDA essentially flat at $15.6M; adjusted net income fell to $0.2M from $6.1M.
- FY2024 revenue guidance reaffirmed $445-$470M; net loss guided $(27)-$(12)M; Adj. EBITDA $16-$35M.
- Cash $90.5M, debt $63.5M; management cites near-term variability in skin substitutes market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661181/000095017024093893/0000950170-24-093893-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661181/000095017024093893/orgo-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093893

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer